Regenerative Medicine Firm Cesca Therapeutics Eyeing Major Device Players
This article was originally published in The Gray Sheet
Executive Summary
The new company, forming from the merger of ThermoGenesis and TotipotentRx, aims to use its cell processing systems and cell formulations to recast the way physicians treat various cardiovascular and orthopedic problems. It is in discussions with device firms about potential partnerships.
You may also be interested in...
FDA Finds Gaps In Cesca's Stem Cell Trial Plan For Critical Limb Ischemia
The agency noted deficiencies in Cesca Therapeutcs' investigational device exemption submission for the CLIRST III pivotal study of its SurgWerks stem cell therapy system in critical limb ischemia. But the company says the overall message for the 224-patient study is positive.
News Briefs: User Fee Bill, Sunshine Mobile Apps, More
The House introduced a bill that would exempt device and drug user fees from sequestration cuts. CMS releases two mobile apps to help track payments required under the Sunshine law. More news.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.